Literature DB >> 27703530

Contrary melanoma-associated antigen-A expression at the tumor front and center: A comparative analysis of stage I and IV head and neck squamous cell carcinoma.

Stefan Hartmann1, Muna Brisam1, Stephan Rauthe2, Oliver Driemel3, Roman C Brands1, Andreas Rosenwald2, Alexander C Kübler1, Urs D A Müller-Richter1.   

Abstract

There is a growing body of evidence indicating that several melanoma-associated antigen-A (MAGE-A) subgroups contribute to the malignancy of head and neck cancer. The present study retrospectively analyzed the expression of all known MAGE-A subgroups in the tumor front and center of 38 head and neck cancer patients (Union for International Cancer Control stage I or IV) by immunohistochemistry. MAGE-A1, -A6, -A8, -A9 and -A11 were expressed at significantly higher levels at the tumor front of stage IV specimens compared with the tumor front of stage I specimens. In stage I cancer, the tumor center and front ratio (C/F ratio) for each subgroup was >1.0. In stage IV cancer, the C/F ratio was <1.0 in 9/11 subgroups. The most significant change in the expression pattern was observed for MAGE-A11. These results indicated that there is a marked alteration and shift to the invasive front of almost all MAGE-A subgroups, but particularly MAGE-A11, during the progression of head and neck squamous cell carcinoma.

Entities:  

Keywords:  A11; head and neck cancer; melanoma-associated antigen; tumor center; tumor front

Year:  2016        PMID: 27703530      PMCID: PMC5038879          DOI: 10.3892/ol.2016.4945

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  25 in total

1.  Induction of MAGE-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma.

Authors:  Caroline J Voskens; Duane Sewell; Ronna Hertzano; Jennifer DeSanto; Sandra Rollins; Myounghee Lee; Rodney Taylor; Jeffrey Wolf; Mohan Suntharalingam; Brian Gastman; John C Papadimitriou; Changwan Lu; Ming Tan; Robert Morales; Kevin Cullen; Esteban Celis; Dean Mann; Scott E Strome
Journal:  Head Neck       Date:  2012-01-27       Impact factor: 3.147

2.  Expression of plasminogen activator inhibitor-1, urokinase receptor and laminin gamma-2 chain is an early coordinated event in incipient oral squamous cell carcinoma.

Authors:  Pia Lindberg; Ake Larsson; Boye Schnack Nielsen
Journal:  Int J Cancer       Date:  2006-06-15       Impact factor: 7.396

3.  Correlation of MAGE-A tumor antigens and the efficacy of various chemotherapeutic agents in head and neck carcinoma cells.

Authors:  S Hartmann; U Kriegebaum; N Küchler; R C Brands; C Linz; A C Kübler; U D A Müller-Richter
Journal:  Clin Oral Investig       Date:  2013-02-21       Impact factor: 3.573

4.  Expression and prognostic value of MAGE-A9 in laryngeal squamous cell carcinoma.

Authors:  Liang Han; Bin Jiang; Hao Wu; Shu Zhang; Xueguan Lu
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

5.  Melanoma-associated antigen expression and the efficacy of tyrosine kinase inhibitors in head and neck cancer.

Authors:  Stefan Hartmann; Roman C Brands; Nora Küchler; Andreas Fuchs; Christian Linz; Alexander C Kübler; Urs D A Müller-Richter
Journal:  Oncol Lett       Date:  2015-06-09       Impact factor: 2.967

6.  Investigation of the expression of melanoma antigen-encoding genes (MAGE-A1 to -A6) in oral squamous cell carcinomas to determine potential targets for gene-based cancer immunotherapy.

Authors:  Jutta Ries; Stefan Schultze-Mosgau; Friedrich Neukam; Elke Diebel; Joerg Wiltfang
Journal:  Int J Oncol       Date:  2005-03       Impact factor: 5.650

7.  MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents.

Authors:  Martin Monte; Marta Simonatto; Leticia Y Peche; Debora R Bublik; Stefania Gobessi; Marco A Pierotti; Monica Rodolfo; Claudio Schneider
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-17       Impact factor: 11.205

8.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

Authors:  P van der Bruggen; C Traversari; P Chomez; C Lurquin; E De Plaen; B Van den Eynde; A Knuth; T Boon
Journal:  Science       Date:  1991-12-13       Impact factor: 47.728

Review 9.  The role of neck dissection in squamous cell carcinoma of the head and neck.

Authors:  Marc Hamoir; Sandra Schmitz; Vincent Gregoire
Journal:  Curr Treat Options Oncol       Date:  2014-12

10.  Analysis of expression profiles of MAGE-A antigens in oral squamous cell carcinoma cell lines.

Authors:  Urs D A Müller-Richter; Albert Dowejko; Tobias Reuther; Johannes Kleinheinz; Torsten E Reichert; Oliver Driemel
Journal:  Head Face Med       Date:  2009-04-09       Impact factor: 2.151

View more
  4 in total

1.  Evolution of Melanoma Antigen-A11 (MAGEA11) During Primate Phylogeny.

Authors:  Christopher S Willett; Elizabeth M Wilson
Journal:  J Mol Evol       Date:  2018-03-24       Impact factor: 2.395

2.  MAGE-A11 expression contributes to cisplatin resistance in head and neck cancer.

Authors:  Stefan Hartmann; Leonie Zwick; Mario J J Scheurer; Andreas R Fuchs; Roman C Brands; Axel Seher; Hartmut Böhm; Alexander C Kübler; Urs D A Müller-Richter
Journal:  Clin Oral Investig       Date:  2017-10-15       Impact factor: 3.573

Review 3.  A Comprehensive Guide to the MAGE Family of Ubiquitin Ligases.

Authors:  Anna K Lee; Patrick Ryan Potts
Journal:  J Mol Biol       Date:  2017-03-11       Impact factor: 5.469

4.  Suppression of MAGE-A10 alters the metastatic phenotype of tongue squamous cell carcinoma cells.

Authors:  Bruna Dos Santos Mendonça; Michelle Agostini; Iara Gonçalves Aquino; Wagner Barbosa Dias; Débora Campanella Bastos; Franklin D Rumjanek
Journal:  Biochem Biophys Rep       Date:  2017-04-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.